학술논문

Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma
Document Type
ConferencePaper
Source
BLOOD. 138
Subject
Medicin och hälsovetenskap
Language
English
English
ISSN
0006-4971